Drug Database
GL

glycopyrrolate + indacaterol (NVA237 + QAB149 / Xoterna Breezhaler / Ultibro Breezhaler)

✓ Approved

Cipla Inc · ADRB2 · Small Molecule

What is glycopyrrolate + indacaterol?

glycopyrrolate + indacaterol is a small molecule developed by Cipla Inc. It is approved for therapeutic indications via inhaled.

Drug Profile

Brand NamesNVA237 + QAB149, Xoterna Breezhaler, Ultibro Breezhaler
CompanyCipla Inc
Drug ClassSmall Molecule
Molecular TargetADRB2, CHRM1, CHRM3
RouteInhaled
StatusApproved
Sources: ClinicalTrials.gov, Cipla Inc

Mechanism of Action

Molecular Targets

glycopyrrolate + indacaterol acts on 3 molecular targets:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

glycopyrrolate + indacaterol is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersChronic obstructive pulmonary disease✓ Approved

Related Research Articles

Unable to load articles right now.

Ask about glycopyrrolate + indacaterol